Over three days, attendees heard from the companies, investors and policymakers shaping what’s next in healthcare, for which highlights included:
On the keynote stage
A keynote discussion offered perspectives on the evolving regulatory landscape and its implications for innovation, investment and patient outcomes. Guests learned how regulatory and scientific collaboration can accelerate meaningful progress in care.
Fireside chats, panels and analyst‑led discussions
Across multiple tracks, senior executives from leading healthcare companies joined Barclays Research analysts for fireside chats and presentations spanning pharmaceuticals, biotechnology, medtech, healthcare services and life sciences tools. Dedicated panels examined topics such as:
- Emerging cardiology and respiratory therapeutics
- The evolution of obesity and metabolic treatments
- Advances in genomics, diagnostics and bioprocessing
- AI‑enabled imaging, robotics and next‑generation care delivery models
Barclays Research experts led deep dives into subsector dynamics, capital allocation trends and where risk and opportunity are diverging across public and private markets.
Spotlight on private innovation
New this year, a private company track brought together investors and founders to highlight emerging biotech companies attracting attention as potential future IPO candidates. Portfolio showcases from Westlake BioPartners and Novo Holdings provided a window into early‑stage innovation and investment themes across the sector.
